1. Signaling Pathways
  2. Immunology/Inflammation
  3. Macrophage migration inhibitory factor (MIF)
  4. Macrophage migration inhibitory factor (MIF) Inhibitor

Macrophage migration inhibitory factor (MIF) Inhibitor

Macrophage migration inhibitory factor (MIF) Inhibitors (27):

Cat. No. Product Name Effect Purity
  • HY-16692
    ISO-1
    Inhibitor 99.84%
    ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM.
  • HY-110063
    4-IPP
    Inhibitor 99.40%
    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
  • HY-17009
    Iguratimod
    Inhibitor 98.49%
    Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.
  • HY-147390
    MIF098
    Inhibitor 99.99%
    MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.
  • HY-P99262
    Imalumab
    Inhibitor 98.37%
    Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.
  • HY-181912
    D-DT/MIF-1-IN-1
    Inhibitor
    D-DT/MIF-1-IN-1 (Compound 4h) is a non-competitive, non-covalent inhibitor of MIF-1 and D-DT, with IC50 values of 2.4 μM and 4.0 μM against D-DT, and an IC50 value of 9.8 μM against MIF-1. D-DT/MIF-1-IN-1 inhibits D-DT-induced phosphorylation of ERK and exerts antiproliferative activity in non-small cell lung cancer cells.
  • HY-182935
    PAANIB-1
    Inhibitor
    PAANIB-1 is a parthanatos associated apoptosis-inducing factor nuclease (PAAN)/macrophage migration inhibitor factor (MIF) inhibitor. PAANIB-1 exhibits neuroprotective activity. PAANIB-1 can be used for the research of Parkinson's disease.
  • HY-130332
    Mitomycin A
    Inhibitor 98.3%
    Mitomycin A is an antitumor agent. Mitomycin A inhibits the spontaneous migration of mouse monocytes. Mitomycin A inhibits the production of MIF (Migration Inhibition Factor) by human lymphocytes. Mitomycin A can be used in the research of tumor diseases.
  • HY-148117
    MD13
    Inhibitor 99.96%
    MD13 is a macrophage migration inhibitory factor (MIF)-directed PROTAC with a Ki of 71 nM. MD13 can be used for cancer research.
  • HY-121356
    Carebastine
    Inhibitor 99.23%
    Carebastine is an Ebastine (HY-B0674) metabolite and H1-receptor antagonist. Carebastine inhibits VEGFR-2 and Akt phosphorylation. Carebastine exerts an anti-inflammatory effect by inhibiting MIF as well as TNF-α and IL-6 production. Carebastine shows anti-angiogenic activity
  • HY-110084
    BTZO-1
    Inhibitor 99.32%
    BTZO-1, a chemical probe, binds to Macrophage migration inhibitory factor (MIF) with a Kd value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro.
  • HY-123814
    4-CPPC
    Inhibitor 98.20%
    4-CPPC is a potent, reversible and selective MIF-2 inhibitor with Ki values of 431, 33 µM for MIF-1, MIF-2, respectively.
  • HY-W164560
    RDR 03785
    Inhibitor
    RDR 03785 is a covalent MIF inhibitor with an IC50 of 0.36 μM.
  • HY-149308
    MKA031
    Inhibitor 98.69%
    MKA031 (compound 6y) is a non-competitive MIF inhibitor with an IC50 value of 1.7 μM. MKA031 (compound 6y) interferes with MIF/AIF interaction, MIF nuclear translocation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced dependent cell death. MKA031 can be used in the study of chronic hepatitis C virus infection.
  • HY-115887
    R110
    Inhibitor 99.90%
    R110 is a potent, competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase with an IC50 of 15 μM. R110 has the potential for the research of cancer diseases.
  • HY-115888
    MIF2-IN-1
    Inhibitor
    MIF2-IN-1 (compound 5d) is a potent inhibitor of MIF2 tautomerase with an IC50 of 1.0 μM. MIF2-IN-1 suppresses the proliferation of non-small cell lung cancer cells by the induction of cell cycle arrest via deactivation of the MAPK pathway. MIF2-IN-1 has the potential for the research of cancer diseases.
  • HY-144196
    MIF-IN-4 hydrochloride
    Inhibitor
    MIF-IN-4 hydrochloride is potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=5.01-6). MIF is a cytokine originally found to play a role in inhibiting macrophage migration.
  • HY-146319
    MIF-IN-6
    Inhibitor
    MIF-IN-6 (compound 2d) is a potent macrophage migration inhibitory factor (MIF) inhibitor with an IC50 of 1.4 μM and a Ki value of 0.96 μM, respectively. MIF-IN-6 attenuates MIF-induced ERK phosphorylation and inhibits proliferation of A549 cells.
  • HY-167880
    BMY-25551
    Inhibitor
    BMY-25551 is a Mitomycin A (HY-130332) analogue that is 8 to 20 times more potent than Mitomycin C (HY-13316) in cytotoxicity to murine and human tumor cell lines. BMY-25551 can be utilized in cancer and hematologic depression research.
  • HY-144190
    MIF-IN-1
    Inhibitor
    MIF-IN-1 (compound 14) is a potent macrophage migration inhibitory factor (MIF) inhibitor (pIC50=6.87).